Dr. Finn on the Phase III PALOMA-2 Trial in ER+ Breast Cancer
Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.
Richard S. Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses the phase III PALOMA-2 trial during an interview at the 2016 ESMO Congress.
PALOMA-2 is a randomized double-blind phase III trial designed to confirm the results of PALOMA-1, which found that the addition of palbociclib (Ibrance) to letrozole (Femara) significantly improved progression-free survival compared with letrozole alone.
Preclinical data has suggested that patients with ER+ breast cancer would specifically benefit from a CDK 4/6 inhibitor such as palbociclib, Finn explains. The current data confirm the agent's consistent efficacy in several different subgroups of biomarkers.
